Therapeutic Effect of Different Doses of Recombinant Human Granulocyte Colony-Stimulating Factor(rhG-CSF) on
Neonatal Sepsis Complicated by Neutropenia

Choi, Moon Young; Jung, Yeon Sook; Son, Dong Woo; Ahn, Hyo Seop

Original Article

Journal of the Korean Pediatric Society 2002;45(4):439-448.
Published online April 15, 2002.

Therapeutic Effect of Different Doses of Recombinant Human Granulocyte Colony-Stimulating Factor(rhG-CSF) on Neonatal Sepsis Complicated by Neutropenia

Moon Young Choi¹, Yeon Sook Jung¹, Dong Woo Son², Hyo Seop Ahn³

¹Department of Pediatrics, Eulji Hospital, Seoul, Korea
²Department of Pediatrics, Bombit Hospital, Seoul, Korea
³Department of Pediatrics, College of Medicine, Seoul National University, Seoul, Korea

호중구 감소증이 합병된 신생아 패혈증에서 Recombinant Human Granulocyte Colony-StimulatingFactor(rhG-CSF)의 투여 용량에 따른 치료 효과

최문영^¹^, 정연숙^¹^, 손동우^²^, 안효섭^³

^¹을지병원 소아과
^²봄빛병원 소아과
^³서울대학교 의과대학 소아과학교실

Correspondence:
Moon Young Choi, Email: mrkorila@hanmail.net

Abstract

Purpose
: The aim of this study is to determine and compare the effects of adjunctive therapy with different doses of recombinant human granulocyte-colony stimulating factor(rhG-CSF) on reversing sepsis-associated neonatal neutropenia, and their survival rate in a group I/II-type trial.
Methods
: RhG-CSF was injected subcutaneously to 10 septic-neutropenic neonates with doses of 10 μg/kg from Oct. 1995 to Sep. 1996, and was administered to another 12 septic-neutropenic neonates with doses of 5 μg/kg from Oct. 1996 to Sep. 1997. Neutrophilic responses and the outcomes of both groups were compared.
Results
: In the rhG-CSF 10 μg/kg treated group and in the 5 μg/kg treated group, the absolute neutrophil count(ANC) was 1,065±89(mean±SEM) and 1,053±131, respectively. The only difference between the two groups was the peak ANC at 48 hours. Eight patients from the remaining nine of rhG-CSF 10 μg/kg treated group(88.9％) and ten in 5 μg/kg treated group(83.3％) survived the sepsis and were discharged without any problems.
Conclusion
: RhG-CSF can increase the neutrophil count in critically ill septic neutropenic neonats. The survival rate of both groups were up to 90％. This finding suggests that both doses of rhG-CSF may be effective in a therapeutically useful time frame to treat septic neonates with neonatal neutropenia attributable to bone marrow supression or neutrophil consumption.

Key Words: Neonatal sepsis, Recombinant human granulocyte colony stimulating factor Neutropenia